The presentation itself is unlikely to move the stock materially unless it reveals unexpected efficacy or safety signals. Traders should watch for the actual presentation on May 30 and any subsequent analyst notes. The key catalyst remains the FDA's NDA decision on lorundrostat, which will determine the stock's trajectory.
Price Chart
Executive Summary
Mineralys Therapeutics announced that new data from its Phase 3 LAUNCH-HTN trial of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease will be presented at ESH 2026 on May 30. The oral presentation highlights the drug's efficacy and safety profile, supporting its NDA under FDA review. This is a routine scientific conference presentation with no new clinical data released in the filing, making it a modest positive catalyst for awareness but not a material event.
Key Facts
- Oral presentation of Phase 3 LAUNCH-HTN data at ESH 2026 on May 30, 2026
- Trial enrolled adults with uncontrolled hypertension on 2-5 medications, randomized to placebo, lorundrostat 50 mg, or 50 mg with optional up-titration to 100 mg
- Primary endpoint: change from baseline in systolic BP at 6 weeks vs placebo
- NDA for lorundrostat is under FDA review
- Lorundrostat has 374-fold selectivity for aldosterone synthase vs cortisol synthase in vitro
Financial Impact
No financial data disclosed; event is a scientific presentation, not a regulatory decision or financial update
Risk Factors
- FDA may issue a Complete Response Letter (CRL) for lorundrostat, delaying or denying approval
- Competition from other aldosterone synthase inhibitors (e.g., baxdrostat) could limit market share
- Clinical data may not replicate in broader populations or show unexpected safety issues
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297012 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | 3 | $26.09 $28.20 | ▲ +8.09% | ▲ +9.83% | $23.56 (−9.70%) |
Jul 23, 2026 10w ago | Insider Cluster | $26.71 $25.65 | ▼ −3.97% | ▼ −7.59% | $23.56 (−11.79%) |
Jul 21, 2026 10w ago | Insider Cluster | $27.52 $26.61 | ▼ −3.31% | ▼ −5.87% | $23.56 (−14.39%) |
Jul 16, 2026 11w ago | Insider Cluster | $27.08 $26.09 | ▼ −3.66% | ▼ −7.27% | $23.56 (−13.00%) |
Jun 30, 2026 13w ago | 144 | $26.89 $26.35 | ▼ −2.01% | ▲ +0.18% | $23.56 (−12.38%) |
Jun 29, 2026 13w ago | 144 | $26.88 $26.71 | ▼ −0.63% | ▼ −0.35% | $23.56 (−12.35%) |
Jun 18, 2026 15w ago | Insider Cluster | $24.63 $27.08 | ▲ +9.95% | ▲ +9.41% | $23.56 (−4.34%) |
Jun 17, 2026 15w ago | 144 | $24.63 $27.08 | ▲ +9.95% | ▲ +9.41% | $23.56 (−4.34%) |
Jun 11, 2026 16w ago | Institutional Cluster | $23.94 $28.96 | ▲ +20.97% | ▲ +19.08% | $23.56 (−1.59%) |
Jun 3, 2026 17w ago | 8-K | $25.06 $27.69 | ▲ +10.49% | ▲ +11.49% | $23.56 (−5.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access